Clinical Trial Update: Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology [Phase 2]

View source ↗

Summary

Phase 2 study evaluating an iodine-131 labeled anti-B1 antibody for first or second relapse indolent B-cell non-Hodgkin lymphoma and lymphomas that have transfo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Iodine-131 anti-B1 antibody (iodine-131 labeled anti-B1 antibody)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: COMPLETED | Results posted: 2012-08-29